Business Context and Reporting Period
This Form 8-K Current Report was filed by Hemispherx Biopharma, Inc. on September 1, 2016, regarding events occurring on August 26, 2016, and August 30, 2016. The filing details a material definitive agreement involving a private placement of equity securities.
Key Financial Metrics and Transaction Details
- Gross Proceeds: $5,000,000 from the sale of 3,333,334 shares of Common Stock and warrants to purchase 2,500,000 shares.
- Net Proceeds: Estimated at approximately $4,650,000 after deducting placement agent fees and transaction expenses.
- Share Price: Common Stock sold at $1.50 per share.
- Warrant Terms: Initial exercise price of $2.00 per share; exercisable six months after issuance for a five-year term.
- Placement Agent Fees: 7% of gross proceeds plus a 1.0% management fee and a $70,000 non-accountable expense allowance.
- Use of Proceeds: Technology transfer preparation, Ampligen manufacturing expenses, working capital, and general corporate purposes.
Material Changes
The filing reports a significant capital raise event rather than operational performance changes. The Company entered into a Securities Purchase Agreement to sell equity and warrants, increasing its cash position upon closing. The closing is expected on or about September 6, 2016, subject to customary conditions.
Outlook, Risks, and Unusual Items
Management Commentary: The Company intends to utilize the net proceeds to advance technology transfer opportunities and support manufacturing for its product, Ampligen.
Risks and Contingencies: The filing includes standard disclaimers that representations and warranties in the Purchase Agreement are for risk allocation between parties and should not be relied upon as factual statements of the Company's condition. The Warrants and shares issuable upon exercise were sold without registration under Section 4(a)(2) and Rule 506 of the Securities Act of 1933.
Investor Verification Checklist
- Confirm the actual closing date of the transaction (expected September 6, 2016) and the final net proceeds received.
- Verify the dilution impact of the 3,333,334 new shares and the potential 2,500,000 shares from investor warrants.
- Review the specific terms of the "Wainwright Warrants" granted to the placement agent (5% of aggregate shares sold, exercise price $1.875).
- Monitor future filings for updates on the status of Ampligen manufacturing and technology transfer initiatives funded by this capital.